Cargando…
Targeted anti-vascular therapies for ovarian cancer: current evidence
Ovarian cancer presents at advanced stage in around 75% of women, and despite improvements in treatments such as chemotherapy, the 5-year survival from the disease in women diagnosed between 1996 and 1999 in England and Wales was only 36%. Over 80% of patients with advanced ovarian cancer will relap...
Autores principales: | Hall, M, Gourley, C, McNeish, I, Ledermann, J, Gore, M, Jayson, G, Perren, T, Rustin, G, Kaye, S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3566823/ https://www.ncbi.nlm.nih.gov/pubmed/23385789 http://dx.doi.org/10.1038/bjc.2012.541 |
Ejemplares similares
-
PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions
por: Ledermann, Jonathan A, et al.
Publicado: (2015) -
Antiangiogenic drugs in ovarian cancer
por: Kumaran, G C, et al.
Publicado: (2009) -
DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents
por: O'Connor, J P B, et al.
Publicado: (2007) -
New perspectives on molecular targeted therapy in ovarian clear cell carcinoma
por: Tan, D S P, et al.
Publicado: (2013) -
Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?
por: Tunariu, N, et al.
Publicado: (2012)